Leonard Schleifer - Regeneron Pharmaceuticals President CEO, Director

REGN -- USA Stock  

Earning Report: November 5, 2019  

  CEO
Dr. Leonard S. Schleifer, M.D., Ph.D., is an President, Chief Executive Officer, Director of the Company. Dr. Schleifer founded the Company in 1988, was a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Regenerons founding scientist, Dr. Yancopoulos, built and has managed the Company over the past nearly 30 years
Age: 65  CEO Since 1994  Ph.D    
914 847-7000  www.regeneron.com
Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology. With nearly 30 years of experience as Chief Executive Officer of the Company, Dr. Schleifer brings to the board an incomparable knowledge of the Company, significant leadership experience, and an indepth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical industry.

Leonard Schleifer Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3 M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records

CEO Since

Murray KesslerPerrigo Company Plc
2018
MARC KIKUCHIDr Reddys Laboratories Ltd
2019
Juan AlaixZoetis
2012
Uwe RohrhoffPerrigo Company Plc
2018
M RamanaDr Reddys Laboratories Ltd
2018
William NieburOrigin Agritech Limited
2016

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Current Sentiment - REGN

Regeneron Pharmaceuticals Investor Sentiment

Majority of Macroaxis users are at this time bullish on Regeneron Pharmaceuticals. What is your perspective on investing in Regeneron Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

REI-UN   
Purchased over 100 shares of
2 days ago
Traded for 24.76
OTEX   
Purchased over 200 shares of
2 days ago
Traded for 53.38
KXS   
Purchased over 60 shares of
2 days ago
Traded for 78.1
IFC   
Purchased over 40 shares of
2 days ago
Traded for 97.23
GDI   
Purchased over 100 shares of
2 days ago
Traded for 29.6
Additionally take a look at Your Equity Center. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Search macroaxis.com